
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
ArriVent BioPharma, Inc. Common Stock (AVBP)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: AVBP (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $39.56
1 Year Target Price $39.56
6 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.3% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 755.39M USD | Price to earnings Ratio - | 1Y Target Price 39.56 |
Price to earnings Ratio - | 1Y Target Price 39.56 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 15.47 - 36.37 | Updated Date 08/15/2025 |
52 Weeks Range 15.47 - 36.37 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.76 | Actual -0.9 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.41% | Return on Equity (TTM) -50.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 519804737 | Price to Sales(TTM) - |
Enterprise Value 519804737 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 40568900 | Shares Floating 24039128 |
Shares Outstanding 40568900 | Shares Floating 24039128 | ||
Percent Insiders 8.24 | Percent Institutions 72.9 |
Upturn AI SWOT
ArriVent BioPharma, Inc. Common Stock
Company Overview
History and Background
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for patients with cancer. They often work on therapies originating in China, aiming to develop and commercialize them globally.
Core Business Areas
- Drug Development and Commercialization: Focuses on in-licensing and developing oncology drugs, particularly those discovered and initially developed in China. Aims for global commercialization with focus on USA and China markets.
Leadership and Structure
Bing Yao, Ph.D., is the current Chief Executive Officer. The company has a management team with experience in drug development and commercialization, and a board of directors with expertise in the pharmaceutical industry. Organizational structure follows typical biotech company structure with research, development, and commercial teams.
Top Products and Market Share
Key Offerings
- Furmonertinib: Furmonertinib is ArriVent's lead product candidate, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed for the treatment of non-small cell lung cancer (NSCLC). The drug has shown potential in treating EGFR-mutated NSCLC. Competitors include Tagrisso (Osimertinib) from AstraZeneca and other EGFR TKIs.
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market. Key trends include targeted therapies, immunotherapies, and personalized medicine. The market is highly competitive and driven by innovation.
Positioning
ArriVent BioPharma is positioned as a company focused on bringing innovative oncology therapies from China to the global market, targeting specific unmet needs in cancer treatment.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. ArriVent aims to capture a portion of this TAM with its targeted therapies, initially focusing on EGFR-mutated NSCLC.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on innovative therapies
- Strategic partnership model
- Lead product candidate with promising clinical data
Weaknesses
- Clinical stage company with no approved products
- Reliance on partnerships
- Relatively small company compared to established pharmaceutical companies
- High risk of drug development failures
Opportunities
- Growing oncology market
- Unmet needs in cancer treatment
- Potential for strategic partnerships
- Expansion into new therapeutic areas
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- AZN
- BMY
- MRK
- PFE
Competitive Landscape
ArriVent faces intense competition from larger, established pharmaceutical companies in the oncology market. ArriVent's advantage lies in its focus on innovative therapies in-licensed from China, but its smaller size and limited resources are disadvantages.
Growth Trajectory and Initiatives
Historical Growth: ArriVent BioPharma's historical growth is defined by its progress in drug development, partnerships, and funding rounds.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its lead product candidate, Furmonertinib. Analyst estimates will be available after the company is more established.
Recent Initiatives: ArriVent's recent initiatives include advancing Furmonertinib through clinical trials and exploring new partnership opportunities.
Summary
ArriVent BioPharma is a clinical-stage company with a promising lead candidate. The company is strategically focused on bringing therapies from China to the global market. Successful clinical trials are the key. It faces high risk and competition from big pharma.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (estimates)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ArriVent BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Newtown Square, PA, United States | ||
IPO Launch date 2024-01-26 | Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://arrivent.com |
Full time employees 52 | Website https://arrivent.com |
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.